Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. - Wikidata - awgldk - TriplyDB

Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.

Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.

http://www.wikidata.org/entity/Q37012737

about

The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History Therapeutic potential of PDE modulation in treating heart disease Phosphodiesterases and cardiac cGMP: evolving roles and controversies The emperor's new clothes: PDE5 and the heart Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice Knockdown of lung phosphodiesterase 2A attenuates alveolar inflammation and protein leak in a two-hit mouse model of acute lung injury.Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy.Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II Volume overload induces differential spatiotemporal regulation of myocardial soluble guanylyl cyclase in eccentric hypertrophy and heart failure Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects.cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy.Phosphodiesterase 2A is a major negative regulator of iNOS expression in lipopolysaccharide-treated mouse alveolar macrophages.Phosphodiesterase inhibition with tadalafil provides longer and sustained protection of stem cells.Sildenafil preserves diastolic relaxation after reduction by L-NAME and increases phosphodiesterase-5 in the intercalated discs of cardiac myocytes and arterioles Prominent expression of phosphodiesterase 5 in striated muscle of the rat urethra and levator ani.Nitric oxide-cyclic GMP signaling in stem cell differentiation PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer Adenoviral short hairpin RNA therapy targeting phosphodiesterase 5a relieves cardiac remodeling and dysfunction following myocardial infarction Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials.Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling network ADAM17 silencing by adenovirus encoding miRNA-embedded siRNA revealed essential signal transduction by angiotensin II in vascular smooth muscle cells.Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition.Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.Phosphodiesterases and cyclic GMP regulation in heart muscle.The role of cGMP in the physiological and molecular responses of the right ventricle to pressure overload.Heart failure with preserved ejection fraction: a clinical dilemma.Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?The clinical dilemma of heart failure with preserved ejection fraction: an update on pathophysiology and management for physicians.Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5.Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo.Regulation and role of myocyte cyclic GMP-dependent protein kinase-1 Controlling myocyte cGMP: phosphodiesterase 1 joins the fray.Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice.Reply to Kass and Takimoto: Cardiac hypertrophy without cGKI and PDE5 in cardiac myocytes.

P2860

Q26741387-41112688-9BD6-404F-99A7-CCEB714BD0E5 Q27005761-2ECC80E3-D4E1-44A0-95FD-E54A5E70990C Q27692588-2723CAF6-40E7-4DBF-91B4-8DF4EF902ED8 Q28543897-B5AD12A0-402C-4931-B106-CCF886112E94 Q28594677-497A2636-BE17-4CC2-9983-8A3AB45A3409 Q29347288-C21B658F-9F90-4C11-A27A-ED9D09EA9AF9 Q33577131-2453F62E-83FE-4273-BAD2-80CFE65B3341 Q33724430-789B57C4-54A4-4DC7-AEB5-5D4AC8DB58A1 Q33769656-F75323BF-34F9-4AA0-BF3A-C45A91694F1A Q33783174-EB7F0CBC-FD15-4C41-A369-83772B6CFADD Q33966155-5844B096-E506-4D54-9889-AE2714C2E460 Q34244951-027A5029-C169-4C8D-A459-0CD544F8BFF1 Q34252901-902992CE-6F7E-49AE-B3C5-8B4DE9FE3E97 Q34277031-CD5EB369-D4F2-42FE-9393-BD52661AD66D Q34279254-883F124D-1133-4BFE-A232-88155887875A Q34341399-51D3EEEA-7E69-470C-8D8C-4A568F6B3335 Q34357737-125EC478-3EB7-42D6-B787-D87608087EE8 Q35141990-83294945-9BF2-4EB9-9984-ECAEF428F7C1 Q35185989-6962EE95-B0D2-478F-9961-7D06C97324B1 Q35596709-2629EF3B-700A-45F7-9C30-C27A3DA78BEC Q35827798-C1CC72E8-9410-48FE-A02D-CCE4719ED8E6 Q35994136-EDFA6B62-A6D5-4327-8F8B-1CB14599E458 Q36128551-79E82A49-4A38-49EC-B8B0-3610B3A630C0 Q36270020-23BCCAC6-B8D1-481C-9627-E63792576834 Q36609843-533DB28F-38F9-4A7B-97FF-2A38D1AB6983 Q37076062-D3C90D6D-E62D-4657-8C41-1ED44CE77C0E Q37245076-3B69D666-A192-4146-88FF-9651073079D2 Q37420916-AAF62DE8-919A-4565-95FC-12F472FB72A4 Q38033089-E61EB604-8033-42E1-B233-DEA83F6C8284 Q38123147-2441DB3F-480C-41C8-B487-3BBC480C60EA Q38195149-CABFBD6F-223C-4C0F-ABDF-BEEF7EAB9DA8 Q38542767-8D354E24-C109-45F3-B404-53969241925D Q38768799-DCC946BF-41B7-40D5-86F1-BA2EB718D893 Q38992600-43D89A80-3A52-43B2-81A6-9FAAD325E3D6 Q42094814-B75011B2-3CD0-47E4-A7C5-028EF18E34EB Q42149439-311D2095-23CD-437F-8A14-63912D6B7388 Q42744811-E9966A70-447B-4A3F-B94E-F17E85228900 Q42905360-330AC170-358B-4E10-8109-FCDD80E51ED4 Q44970917-6D83B76D-2B53-405A-A011-2733FBDBB4D8 Q46982888-75212674-D1EC-4CE4-9A87-DA56B11AB9A7

P2860

Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.

http://www.wikidata.org/entity/Q37012737

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 August 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.

@en

Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.

@nl

type

label

Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.

@en

Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.

@nl

prefLabel

Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.

@en

Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.

@nl

P1433

Q37012737-74C8DC61-3164-4C30-B4F7-B91280B3A505

P1476

Q37012737-FE18CE22-11D5-4C6C-90FE-61D33239937C

P2093

Q37012737-165ADB56-0502-47A9-9476-EF139673C007

Q37012737-1940F630-4E91-4EE4-9DDE-E371CB587BE9

Q37012737-2FB01512-A4C1-4066-A464-F73FD1F90CBE

Q37012737-3DFF2F93-2E64-4B90-A558-CA4FE3951CE3

Q37012737-43E22978-3BF1-49FD-AF0A-41E7C18634A9

Q37012737-7BA1000A-22FB-4FF2-A6E2-42F6CCD5BCA9

Q37012737-AA9C9B87-1A1E-4C9E-AB73-06724DC9B2F3

Q37012737-BF0BDF37-69BC-48F6-B4D5-375BA917BB73

Q37012737-EBB9A902-6BAD-40D0-81A2-208778FF70BD

Q37012737-EFC27E25-4267-4AD1-82BF-7EB91A54409A

P2860

Q37012737-0564ACD2-DEA3-4C11-9F64-800ED3933759

Q37012737-06C1D19B-39F0-4687-AFF7-DBC7E6FB0545

Q37012737-0781B96A-0845-4D6A-A800-654034A0FF56

Q37012737-0979A146-76D5-42BA-A21B-824C02890422

Q37012737-13DBCF26-06F0-48B9-ABF8-F1C7FB0E6A5D

Q37012737-17A08D42-020B-4885-949A-B13E9D4F1848

Q37012737-2C54D88B-27E3-4C56-A8C7-5B92F7712F08

Q37012737-2D46671F-F8D7-44EC-BCCC-8B1A8BEA9B45

Q37012737-35C8DCF7-C42C-4627-82F2-36F686D5E545

Q37012737-3F730226-8E44-44C2-A09E-45844ABF91A5

P304

Q37012737-EEF07003-B39C-41DF-B614-BD7ADB35C013

P31

Q37012737-AE246656-4804-4AAD-8F29-91AF2BF90694

P356

Q37012737-A103B528-7BBD-4E38-957A-E6BFFD3695B8

P433

Q37012737-A99B6070-B423-4438-9626-D50D6EBF357D

P478

Q37012737-E6645BDC-3A96-4C9B-B71F-31FBBB8E4523

P577

Q37012737-327557A8-7EEF-4C9D-9DD7-75376E8936C5

P5875

Q37012737-AD551AB8-3633-4598-A686-53279DC0CA83

P698

Q37012737-AA740485-6AA3-4270-8AD2-4C32FA14DB3E

P932

Q37012737-4FD8E7C8-F343-4403-A294-40E9B087FED1

P356

J.CELLSIG.2008.08.012

P1433

Cellular Signalling

P1476

Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.

@en

P2093

Brian O'Rourke

http://www.w3.org/2001/XMLSchema#string

David A Kass

http://www.w3.org/2001/XMLSchema#string

Eiki Takimoto

http://www.w3.org/2001/XMLSchema#string

Hunter C Champion

http://www.w3.org/2001/XMLSchema#string

Manling Zhang

http://www.w3.org/2001/XMLSchema#string

Michael T Crow

http://www.w3.org/2001/XMLSchema#string

Ning Feng

http://www.w3.org/2001/XMLSchema#string

Norimichi Koitabashi

http://www.w3.org/2001/XMLSchema#string

Ryan Rambaran

http://www.w3.org/2001/XMLSchema#string

Takahiro Nagayama

http://www.w3.org/2001/XMLSchema#string

P2860

Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155.

Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use

Potency, selectivity, and consequences of nonselectivity of PDE inhibition

Overall cardiovascular profile of sildenafil citrate

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility

Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.

Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution and subcellular localization of PDE9A variants.

Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes.

Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil.

Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes

P304

2231-2236

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CELLSIG.2008.08.012

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23255038

http://www.w3.org/2001/XMLSchema#string

P698

18790048

http://www.w3.org/2001/XMLSchema#string

P932

2601628

http://www.w3.org/2001/XMLSchema#string